
The gastrointestinal (GI) tract is a major site of ulcerative, inflammatory, and neoplastic diseases. It also functions as an important interface in systemic metabolic regulation. The effectiveness of current treatments is often limited by poor drug stability and short residence times in the GI tract, insufficient exposure at the target site, and unnecessary systemic exposure. These limitations are compounded by regional pH changes, digestive enzymes, mucus turnover, peristaltic clearance, immune surveillance, and microbial metabolism. Advanced biomedical materials, including mucoadhesive hydrogels, stimuli-responsive nanoplatforms, metal–organic frameworks (MOFs), and extracellular matrix (ECM)-derived scaffolds, are increasingly being developed to protect cargo, prolong mucosal residence, enable site-selective release, support tissue repair, and modulate immune or microbial processes. However, selecting a suitable material and delivery strategy for different GI diseases remains challenging. This review examines physiological barriers to drug delivery in the GI tract, classifies advanced biomaterials and delivery systems by therapeutic function and platform type, and evaluates their applications across GI diseases with attention to administration routes, target sites, therapeutic outcomes, and clinical translation. Finally, we discuss future priorities for route-specific material design, human-relevant evaluation, and the safe development of advanced delivery systems. This review aims to provide a practical reference for selecting appropriate biomaterials and delivery systems for GI disease treatment and for guiding their further development toward clinical use.
The development of advanced therapies for stroke, spinal cord injury, and neurodegenerative diseases—primary causes of death, disability and dementia—requires a comprehensive understanding of the interplay between excitotoxicity, aberrant neurotrophic-signalling, glial reactivity, and neuroinflammation. Recent evidence has identified the truncated neurotrophin receptor TrkB-T1 as a potential master regulator of these processes. TrkB-T1 levels increase after stroke whereas the pro-survival full-length isoform (TrkB-FL) decreases. Furthermore, stroke-induced excitotoxicity triggers TrkB-T1 regulated intramembrane proteolysis (RIP), which produces TrkB-T1-ICD, a poorly characterised fragment containing the receptor intracellular domain and a few transmembrane amino acids. This study investigated whether the TrkB-T1 intracellular domain intrinsically contributes to neurotoxicity, reactive gliosis, and neuroinflammation. Our results predict that TrkB-T1 RIP generates a nuclear localization signal in TrkB-T1-ICD that might support nuclear translocation and injury-induced transcriptional regulation in neurons undergoing excitotoxicity. Using cell-penetrating peptides (CPPs), we generated a TrkB-T1-ICD mimetic peptide (Bio-LTT1Ct) containing the TrkB-T1 intracellular region. Bio-LTT1Ct translocated to the nucleus of neurons and astrocytes, provoking cell death and inducing early transcriptional changes in neurons, resembling those triggered by excitotoxicity. In vivo, intranasally administrated Bio-LTT1Ct was brain-permeable and distributed within cortical neurons and astrocytes across both hemispheres. Notably, Bio-LTT1Ct administration was sufficient to promote TrkB isoform imbalance, glial reactivity, and acquisition of proinflammatory profiles, all considered stroke hallmarks. In conclusion, these results imply that TrkB-T1 RIP might be a central mechanism of ischaemic damage and identify the receptor’s intracellular region as sufficient to recapitulate stroke-like effects, marking this pathological mechanism as a critical target for therapy.
Osteoarthritis (OA) is a heterogeneous whole-joint disease and a leading cause of pain and disability worldwide. Its development and progression reflect complex interactions among ageing, genetic susceptibility, mechanical stress, inflammation, and metabolic dysfunction. This review integrates current knowledge of OA epidemiology, risk factors, molecular pathogenesis, and therapeutic advances, with particular emphasis on lipid metabolism as an emerging regulator of joint homeostasis. We introduce lipid metabolic coding as a conceptual framework describing how lipid-derived substrates and signals are processed in a context-dependent manner to influence cellular identity, stress responses, and inter-tissue communication. Altered fatty-acid metabolism, de novo lipogenesis, lipid-droplet turnover, cholesterol handling, and post-translational modifications may contribute to cartilage degeneration and whole-joint pathology. We further discuss four overlapping, potentially stage-dependent lipid-associated endotypes as testable models rather than established clinical classifications. Although experimental evidence identifies promising metabolic targets, their causal relevance and therapeutic utility in human OA remain incompletely defined. Integrating longitudinal clinical data with spatial multi-omics and functional validation may clarify these mechanisms and support the development of more precisely targeted, disease-modifying therapies.